Home › Calculator › EKTAY Dividend Calculator 2026
EKTAY Dividend DRIP Calculator 2026
4.95% YieldHealthcareElekta AB (publ) · OTC
Price: $5.22 · Annual div: $0.26/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When EKTAY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your EKTAY snowball 📈
$10,000 in EKTAY → $125.1K in 10 years · $1,165.72/month
About Elekta AB (publ) (EKTAY) — Dividend Analysis 2026
Elekta AB (publ) is a global medical technology company dedicated to developing and delivering advanced clinical solutions for the treatment of cancer and brain disorders. Its comprehensive portfolio includes innovative radiotherapy systems such as the Elekta Unity MR-Linac, the Elekta Harmony linear accelerator, Elekta Infinity for diverse patient radiotherapy requirements, and the Elekta Synergy digital accelerator for advanced image-guided radiation therapy. Specific solutions like Versa HD are available for managing brain metastases. The company also supplies crucial treatment management software, automated and integrated quality assurance tools, and hardware and software for motion management. Further augmenting its oncology offerings, Elekta provides MOSAIQ Plaza for integrated multidisciplinary cancer care and Elekta Axis Cloud for managed hosting. Within brachytherapy, key products include the image-guided Elekta Studio, the mobile ImagingRing CT scanner, Oncentra Brachy for streamlining repetitive tasks, the Elekta Flexitron afterloader for precise workflow execution, and specialized applicators like Venezia and Geneva for cervical cancer treatment. For neurological conditions, Elekta offers a suite of advanced radiosurgery and neurosurgery solutions. This includes the Leksell Gamma Knife series – Icon for personalized radiation treatment, Perfexion for neurosurgical applications, and Lightning for accelerated procedures. Its neurosurgery product line features the Leksell Vantage Stereotactic System for intracranial interventions and the Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. Founded in 1972, Elekta maintains its corporate headquarters in Stockholm, Sweden.
Compare EKTAY with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full EKTAY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open EKTAY position with:
🌍 EKTAY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold EKTAY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 4.95% | 2.15% | $495 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 4.21% | 1.41% | $421 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3.96% | 1.16% | $396 / yr |
| 🇬🇧 UK ISA | 0% | 4.95% | 2.15% | $495 / yr |
| 🇬🇧 UK Taxable | 8.75% | 4.52% | 1.72% | $452 / yr |
| 🇨🇦 TFSA | 0% | 4.95% | 2.15% | $495 / yr |
| 🇨🇦 CA Taxable | 25% | 3.71% | 0.91% | $371 / yr |
| 🇦🇺 Super (pension) | 15% | 4.21% | 1.41% | $421 / yr |
| 🇦🇺 AU Taxable | 30% | 3.46% | 0.67% | $347 / yr |
| 🇩🇪 DE Taxable | 26.375% | 3.64% | 0.84% | $364 / yr |
| 🇫🇷 FR Taxable | 30% | 3.46% | 0.67% | $347 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 EKTAY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.26/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 EKTAY Dividend Payment Schedule
EKTAY pays quarterly — 4 times per year. Next ex-div: TBD.
📊 EKTAY vs Healthcare Benchmarks
How EKTAY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for EKTAY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ EKTAY Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the EKTAY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Elekta AB (publ) (EKTAY) is currently trading at $5.22, 65% below its 52-week high. The current dividend yield is 4.95% based on an annual payout of $0.26 per share.
EKTAY (Elekta AB (publ)) — 4.95% Dividend Yield Analysis
Elekta AB (publ) (EKTAY) is a healthcare stock currently trading at $5.22 with a dividend yield of 4.95%. The company pays an annual dividend of $0.26 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, EKTAY has grown its dividend at a compound annual rate of 30.2%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.